George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDDDD.L Regulatory News (DDDD)

  • There is currently no data for DDDD

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

11 Mar 2020 09:49

RNS Number : 7644F
4d Pharma PLC
11 March 2020
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

 

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

4d pharma plc

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

 

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

 

An acquisition or disposal of financial instruments

 

An event changing the breakdown of voting rights

 X

Other (please specify)iii:

 

3. Details of person subject to the notification obligationiv

Name

Link Fund Solutions Ltd

City and country of registered office (if applicable)

6th Floor, 65 Gresham Street, London EC2V 7NQ, United Kingdom

4. Full name of shareholder(s) (if different from 3.)v

Name

 

City and country of registered office (if applicable)

 

5. Date on which the threshold was crossed or reachedvi:

10/03/2020

6. Date on which issuer notified (DD/MM/YYYY):

10/03/2020

7. Total positions of person(s) subject to the notification obligation

 

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

11.96%

 

11.96%

109,493,842

Position of previous notification (if

applicable)

19.99%

 

19.99%

 

       

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

GB00BJL5BR07

13,091,131

 

11.96%

 

 

 

 

 

 

SUBTOTAL 8. A

 

 

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

 

 

 

 

 

 

 

SUBTOTAL 8. B 1

 

 

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

 

 

 

 

 

 

 

 

 

SUBTOTAL 8.B.2

 

 

 

 

 

 

 

 

 

 

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

X

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

 

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Link Fund Solutions Ltd

11.96%

 

11.96%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

10. In case of proxy voting, please identify:

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

 

11. Additional informationxvi

 

     

 

Place of completion

6th Floor, 65 Gresham Street, London EC2V 7NQ, United Kingdom

Date of completion

10/03/2020

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
HOLFIFSAVRILLII
Date   Source Headline
18th Mar 20204:39 pmRNSPrice Monitoring Extension
18th Mar 20207:49 amRNSDirector/PDMR Shareholding
17th Mar 20207:00 amRNSAdditional Interim Clinical Data
16th Mar 20207:00 amRNSParticipation in Chardan Conference
11th Mar 20209:49 amRNSHolding(s) in Company
11th Mar 20207:00 amRNSHolding(s) in Company
9th Mar 202011:07 amRNSResult of Meeting
21st Feb 20202:25 pmRNSHolding(s) in Company
19th Feb 20202:06 pmRNSPosting of Circular
18th Feb 20206:28 pmRNSResult of Placing
18th Feb 20207:00 amRNSLaunch of Placing
7th Feb 20203:18 pmRNSHolding(s) in Company
6th Jan 20207:00 amRNSClinical Update
4th Dec 201911:22 amRNSHolding(s) in Company
29th Nov 201911:19 amRNSHolding(s) in Company
8th Nov 201911:27 amRNSHolding(s) in Company
6th Nov 20197:00 amRNSClinical Observations from MRx0518
5th Nov 20195:36 pmRNSHolding(s) in Company
4th Nov 201912:22 pmRNSHolding(s) in Company
4th Nov 201912:04 pmRNSHolding(s) in Company
17th Oct 201911:17 amRNSHolding(s) in Company
15th Oct 20192:51 pmRNSHolding(s) in Company
8th Oct 20197:00 amRNSCollaboration with MSD
30th Sep 20197:00 amRNSInterim Results
27th Sep 201912:23 pmRNSHolding(s) in Company
26th Sep 201911:40 amRNSHolding(s) in Company
23rd Sep 20197:00 amRNSPublication of data on neurodegenerative disease
20th Sep 20191:28 pmRNSHolding(s) in Company
20th Sep 20191:19 pmRNSHolding(s) in Company
20th Sep 201911:20 amRNSHolding(s) in Company
27th Aug 20197:00 amRNSAppointment of NED
25th Jul 20197:00 amRNSOncology Programmes Update
8th Jul 20193:51 pmRNSHolding(s) in Company
8th Jul 20197:00 amRNSClinical Update
1st Jul 20197:00 amRNSChange of Adviser
20th Jun 201910:38 amRNSResult of AGM
3rd Jun 20197:00 amRNS4D presents MRx0518 combination study at ASCO
30th May 20197:00 amRNSDirector/PDMR Shareholding
28th May 20192:50 pmRNSAnnual Report and Notice of AGM
23rd May 20197:00 amRNSDirector/PDMR Shareholding
22nd May 20197:00 amRNSDirector/PDMR Shareholding
21st May 20197:00 amRNSFinal Results
16th May 20197:00 amRNS4D Presents Phase Ib Clinical Data on Thetanix®
13th May 20198:00 amRNSParticipation in Conferences
29th Apr 20197:00 amRNSClinical Update - MRx0518 oncology programmes
14th Mar 20197:00 amRNSDirector/PDMR Shareholding
13th Mar 20199:08 amRNSDirector/PDMR Shareholding
8th Mar 20197:00 amRNSParticipation in Microbiome Conference
29th Jan 20197:00 amRNSPublication of data in connection with MRx0518
7th Jan 20197:00 amRNSCollaboration with MD Anderson Cancer Center

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.